Royal Emerald Pharmaceuticals Importer Application Notice
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
Royal Emerald Pharmaceuticals is applying to import certain controlled substances into the US. They aim to use these imports for research and medicinal purposes, not for commercial resale. Stakeholders can submit comments or request a hearing until May 18, 2026.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Royal Emerald Pharmaceuticals seeks permission to import controlled substances.
- Imports to be used for non-commercial research and medicinal purposes.
- Stakeholders have until May 18, 2026, to comment or request a hearing.
Obligations
What this law requires
Registered bulk manufacturers of the affected basic class(es) of controlled substance(s) must submit electronic comments or objections to the issuance of the proposed registration.
Royal Emerald Pharmaceuticals must submit electronic comments or objections to the issuance of the proposed registration for importing controlled substances by May 18, 2026.
Royal Emerald Pharmaceuticals must submit all requests for a hearing to the Drug Enforcement Administration at specified addresses by May 18, 2026.
Any party may file a written request for a hearing on the application regarding the registration.
Royal Emerald Pharmaceuticals must ensure that all imported controlled substances are used only for legitimate medical, scientific, research, and/or industrial purposes.